-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2024-511253-21-00
3
2025-02-28
Thoracic tumors with homozygous MTAP-deletion
-
2024-515538-34-00
10
2025-02-27
Head and Neck Squamous Cell Carcinoma
-
2023-505394-32-00
5
2025-02-06
chronic graft versus host disease
-
2024-510969-42-00
4
2024-09-30
Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapse
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2022-502465-18-00
9
2024-02-15
Advanced or metastatic breast cancer
-
2023-503452-27-00
5
2024-01-02
Adult patients with follicular B-cell non-Hodgkin lymphoma grade 1-3A,
-
2023-503669-50-00
5
2023-12-27
Moderate-to-Severe Thyroid Eye Disease
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2023-503652-27-00
5
2023-10-06
Melanoma
-
2022-501346-30-00
5
2023-09-25
Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
-
2022-502322-41-00
5
2023-09-12
Metastatic breast cancer
-
2022-500637-80-00
5
2023-03-28
gastrointestinal stromal tumor
-
2023-504091-23-00
4
2023-03-14
Grade 1 Endometrial Cancer
-
2024-517205-82-00
4
2023-01-20
adrenocortical carcinoma
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2022-501380-40-00
4
2022-08-10
Diffuse large B-cell lymphoma (DLBCL)
-
2023-506361-56-00
5
2022-04-01
Endometrial cancer